{
    "xml": "<topic id=\"PHP34179\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/regorafenib\" basename=\"regorafenib\" title=\"REGORAFENIB\">\n<title>REGORAFENIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1274\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/regorafenib\">Regorafenib</xref>\n</p>\n<data name=\"vtmid\">703808002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_208007314\" title=\"Protein kinase inhibitors\">Protein kinase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP42863\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/regorafenib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Regorafenib is an inhibitor of several protein kinases.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42817\" outputclass=\"indicationsAndDose\" rev=\"1.15\" parent=\"/drugs/regorafenib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic colorectal cancer in patients who have previously been treated with, or who are unsuitable for standard treatment including fluoropyrimidine-based chemotherapy, a vascular endothelial growth factor inhibitor, and an epidermal growth factor receptor inhibitor</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>160&#8239;mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustment due to side effects&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42873\" outputclass=\"importantSafetyInformation\" rev=\"1.9\" parent=\"/drugs/regorafenib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42920\" outputclass=\"cautions\" rev=\"1.17\" parent=\"/drugs/regorafenib\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Ensure measures to prevent hand-foot skin reaction</ph>; <ph outputclass=\"caution\">Gilbert&#8217;s syndrome&#8212;risk of hyperbilirubinaemia</ph>; <ph outputclass=\"caution\">history of ischaemic heart disease&#8212;monitor for signs and symptoms of myocardial ischaemia and interrupt treatment if signs of ischaemia or infarction develop</ph>; <ph outputclass=\"caution\">hypertension&#8212;control blood pressure before treatment initiation and monitor as clinically indicated during treatment (review dose and consider treatment interruption if severe or persistent hypertension develops; discontinue treatment if hypertensive crisis occurs)</ph>; <ph outputclass=\"caution\">may impair wound healing&#8212; withhold treatment for major surgical procedures</ph>; <ph outputclass=\"caution\">predisposition to bleeding</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42809\" outputclass=\"interactions\" rev=\"1.13\" parent=\"/drugs/regorafenib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (regorafenib).</p>\n<p>Caution in concomitant treatment with drugs that may increase the risk of bleeding (increased risk of haemorrhagic events).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42732\" outputclass=\"sideEffects\" rev=\"1.17\" parent=\"/drugs/regorafenib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abnormal international normalised ratio</ph>; <ph outputclass=\"sideEffect\">biochemical disturbances</ph>; <ph outputclass=\"sideEffect\">decreased appetite</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dry mouth</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dysphonia</ph>; <ph outputclass=\"sideEffect\">electrolyte disturbances</ph>; <ph outputclass=\"sideEffect\">gastro-enteritis</ph>; <ph outputclass=\"sideEffect\">gastro-oesophageal reflux</ph>; <ph outputclass=\"sideEffect\">haemorrhage (including fatal)</ph>; <ph outputclass=\"sideEffect\">hand-foot skin reaction</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypothyroidism</ph>; <ph outputclass=\"sideEffect\">infection</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">mucosal inflammation</ph>; <ph outputclass=\"sideEffect\">musculoskeletal stiffness</ph>; <ph outputclass=\"sideEffect\">nail disorder</ph>; <ph outputclass=\"sideEffect\">pain</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">taste disorders</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">weight loss</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gastro-intestinal perforation and fistula (discontinue treatment)</ph>; <ph outputclass=\"sideEffect\">hypertensive crisis</ph>; <ph outputclass=\"sideEffect\">myocardial infarction</ph>; <ph outputclass=\"sideEffect\">myocardial ischaemia</ph>; <ph outputclass=\"sideEffect\">severe (including fatal) liver injury</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Keratoacanthoma</ph>; <ph outputclass=\"sideEffect\">posterior reversible encephalopathy syndrome</ph>; <ph outputclass=\"sideEffect\">squamous cell carcinoma of the skin</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hand-foot skin reaction</p>\n<p>Consult product literature if signs or symptoms develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42900\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/regorafenib\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Women of childbearing potential and men must use effective contraception during treatment and up to 8 weeks after last dose.</p>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42794\" outputclass=\"pregnancy\" parent=\"/drugs/regorafenib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42932\" outputclass=\"breastFeeding\" parent=\"/drugs/regorafenib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42840\" outputclass=\"hepaticImpairment\" parent=\"/drugs/regorafenib\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42775\" outputclass=\"renalImpairment\" parent=\"/drugs/regorafenib\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in severe impairment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42690\" outputclass=\"monitoringRequirements\" parent=\"/drugs/regorafenib\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor blood count and coagulation parameters and consider permanent discontinuation in event of severe bleeding.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor hepatic function before treatment, then at least every two weeks for the first 2 months, then at least monthly thereafter and as clinically indicated&#8212;consult product literature if changes in liver function observed.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (including seizure, headache, altered mental status, visual disturbances or cortical blindness, with or without hypertension)&#8212;discontinue treatment if symptoms occur.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor biochemical, electrolyte and metabolic parameters during treatment; ensure measures to prevent hand-foot skin reaction&#8212;consult product literature if signs or symptoms develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42967\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/regorafenib\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Tablets should be taken at the same time each day, swallowed whole with water after a light meal that contains less than 30% fat.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42786\" outputclass=\"patientAndCarerAdvice\" rev=\"1.13\" parent=\"/drugs/regorafenib\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Counselling advised (administration).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34179-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/regorafenib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75587\" title=\"Tablet\" namespace=\"/drugs/regorafenib/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1274\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/regorafenib\" title=\"Regorafenib\" count=\"1\" rel=\"link\">Regorafenib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75587\" namespace=\"/drugs/regorafenib/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP34179",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/regorafenib",
    "basename": "regorafenib",
    "title": "REGORAFENIB",
    "interactants": [
        {
            "id": "bnf_int_1274",
            "label": "Regorafenib"
        }
    ],
    "vtmid": "703808002",
    "drugClassification": [
        "Protein kinase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Regorafenib is an inhibitor of several protein kinases.",
                "html": "<p>Regorafenib is an inhibitor of several protein kinases.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of metastatic colorectal cancer in patients who have previously been treated with, or who are unsuitable for standard treatment including fluoropyrimidine-based chemotherapy, a vascular endothelial growth factor inhibitor, and an epidermal growth factor receptor inhibitor",
                        "html": "Treatment of metastatic colorectal cancer in patients who have previously been treated with, or who are unsuitable for standard treatment including fluoropyrimidine-based chemotherapy, a vascular endothelial growth factor inhibitor, and an epidermal growth factor receptor inhibitor"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "160 mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustment due to side effects&#8212;consult product literature.",
                        "html": "<p>160&#8239;mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustment due to side effects&#8212;consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Ensure measures to prevent hand-foot skin reaction",
                "html": "Ensure measures to prevent hand-foot skin reaction"
            },
            {
                "type": "cautions",
                "textContent": "Gilbert&#8217;s syndrome&#8212;risk of hyperbilirubinaemia",
                "html": "Gilbert&#8217;s syndrome&#8212;risk of hyperbilirubinaemia"
            },
            {
                "type": "cautions",
                "textContent": "history of ischaemic heart disease&#8212;monitor for signs and symptoms of myocardial ischaemia and interrupt treatment if signs of ischaemia or infarction develop",
                "html": "history of ischaemic heart disease&#8212;monitor for signs and symptoms of myocardial ischaemia and interrupt treatment if signs of ischaemia or infarction develop"
            },
            {
                "type": "cautions",
                "textContent": "hypertension&#8212;control blood pressure before treatment initiation and monitor as clinically indicated during treatment (review dose and consider treatment interruption if severe or persistent hypertension develops; discontinue treatment if hypertensive crisis occurs)",
                "html": "hypertension&#8212;control blood pressure before treatment initiation and monitor as clinically indicated during treatment (review dose and consider treatment interruption if severe or persistent hypertension develops; discontinue treatment if hypertensive crisis occurs)"
            },
            {
                "type": "cautions",
                "textContent": "may impair wound healing&#8212; withhold treatment for major surgical procedures",
                "html": "may impair wound healing&#8212; withhold treatment for major surgical procedures"
            },
            {
                "type": "cautions",
                "textContent": "predisposition to bleeding",
                "html": "predisposition to bleeding"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (regorafenib).\n\nCaution in concomitant treatment with drugs that may increase the risk of bleeding (increased risk of haemorrhagic events).",
                "html": "<p>Appendix 1 (regorafenib).</p><p>Caution in concomitant treatment with drugs that may increase the risk of bleeding (increased risk of haemorrhagic events).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abnormal international normalised ratio",
                        "html": "Abnormal international normalised ratio",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "biochemical disturbances",
                        "html": "biochemical disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "decreased appetite",
                        "html": "decreased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry mouth",
                        "html": "dry mouth",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dysphonia",
                        "html": "dysphonia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "electrolyte disturbances",
                        "html": "electrolyte disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-enteritis",
                        "html": "gastro-enteritis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-oesophageal reflux",
                        "html": "gastro-oesophageal reflux",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage (including fatal)",
                        "html": "haemorrhage (including fatal)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hand-foot skin reaction",
                        "html": "hand-foot skin reaction",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypothyroidism",
                        "html": "hypothyroidism",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "infection",
                        "html": "infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "mucosal inflammation",
                        "html": "mucosal inflammation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "musculoskeletal stiffness",
                        "html": "musculoskeletal stiffness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nail disorder",
                        "html": "nail disorder",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pain",
                        "html": "pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "taste disorders",
                        "html": "taste disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight loss",
                        "html": "weight loss",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Gastro-intestinal perforation and fistula (discontinue treatment)",
                        "html": "Gastro-intestinal perforation and fistula (discontinue treatment)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypertensive crisis",
                        "html": "hypertensive crisis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "myocardial infarction",
                        "html": "myocardial infarction",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "myocardial ischaemia",
                        "html": "myocardial ischaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "severe (including fatal) liver injury",
                        "html": "severe (including fatal) liver injury",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Keratoacanthoma",
                        "html": "Keratoacanthoma",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "posterior reversible encephalopathy syndrome",
                        "html": "posterior reversible encephalopathy syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "squamous cell carcinoma of the skin",
                        "html": "squamous cell carcinoma of the skin",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hand-foot skin reaction",
                "textContent": "Consult product literature if signs or symptoms develop.",
                "html": "<p>Consult product literature if signs or symptoms develop.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Women of childbearing potential and men must use effective contraception during treatment and up to 8 weeks after last dose.\n\nExclude pregnancy before treatment with cytotoxic drugs.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Women of childbearing potential and men must use effective contraception during treatment and up to 8 weeks after last dose.</p><p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in animal studies.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in moderate impairment.\n\nAvoid in severe impairment.",
                "html": "<p>Manufacturer advises caution in moderate impairment.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in severe impairment&#8212;no information available.",
                "html": "<p>Caution in severe impairment&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor blood count and coagulation parameters and consider permanent discontinuation in event of severe bleeding.",
                "html": "<p>Monitor blood count and coagulation parameters and consider permanent discontinuation in event of severe bleeding.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor hepatic function before treatment, then at least every two weeks for the first 2 months, then at least monthly thereafter and as clinically indicated&#8212;consult product literature if changes in liver function observed.",
                "html": "<p>Monitor hepatic function before treatment, then at least every two weeks for the first 2 months, then at least monthly thereafter and as clinically indicated&#8212;consult product literature if changes in liver function observed.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (including seizure, headache, altered mental status, visual disturbances or cortical blindness, with or without hypertension)&#8212;discontinue treatment if symptoms occur.",
                "html": "<p>Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (including seizure, headache, altered mental status, visual disturbances or cortical blindness, with or without hypertension)&#8212;discontinue treatment if symptoms occur.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor biochemical, electrolyte and metabolic parameters during treatment; ensure measures to prevent hand-foot skin reaction&#8212;consult product literature if signs or symptoms develop.",
                "html": "<p>Monitor biochemical, electrolyte and metabolic parameters during treatment; ensure measures to prevent hand-foot skin reaction&#8212;consult product literature if signs or symptoms develop.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Tablets should be taken at the same time each day, swallowed whole with water after a light meal that contains less than 30% fat.",
                "html": "<p>Tablets should be taken at the same time each day, swallowed whole with water after a light meal that contains less than 30% fat.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Counselling advised (administration).",
                "html": "<p>Counselling advised (administration).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75587",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1274",
                "label": "Regorafenib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75587",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}